Cancer Lett.
1995
,
94
, 79−83
15) Rodrigues, Fiona C., et al. “Developments in the Anticancer Activity of Structurally Modified
Curcumin: An up-to-Date Review.”
European Journal of Medicinal Chemistry
, vol. 177, 2019,
pp. 76–104., doi:10.1016/j.ejmech.2019.04.058.
45
16) Paulraj, Felicia, et al. “Molecular Pathways Modulated by Curcumin Analogue,
Diarylpentanoids in Cancer.”
Biomolecules
, vol. 9, no. 7, Oct. 2019, p. 270.,
doi:10.3390/biom9070270.
17) Dai, Fang, et al. “Insights into the Importance for Designing Curcumin-Inspired Anticancer
Agents by a Prooxidant Strategy: The Case of Diarylpentanoids.”
Free Radical Biology and
Medicine
, vol. 85, 2015, pp. 127–137., doi:10.1016/j.freeradbiomed.2015.04.017.
18) Weber, Waylon M., et al. “Activation of NFκB Is Inhibited by Curcumin and Related
Enones.”
Bioorganic & Medicinal Chemistry
, vol. 14, no. 7, 2006, pp. 2450–2461.,
doi:10.1016/j.bmc.2005.11.035.
19) Heinlein, Cynthia A, and Chawnshang Chang. “Androgen Receptor in Prostate
Cancer.”
Endocrine Reviews
, U.S. National Library of Medicine, Apr. 2004,
www.ncbi.nlm.nih.gov/pubmed/15082523.
20) Fajardo, Alexandra M, et al. “Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated
Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer
Cells.”
PloS One
, Public Library of Science, 17 Mar. 2016.
21) Xu, Guanhong, et al. “The Three Dimensional Quantitative Structure Activity Relationships
(3D-QSAR) and Docking Studies of Curcumin Derivatives as Androgen Receptor
Antagonists.”
International Journal of Molecular Sciences
, vol. 13, no. 5, 2012, pp. 6138–6155.,
doi:10.3390/ijms13056138.
46
22) Ohtsu, Hironori, et al. “Antitumor Agents. 217.†Curcumin Analogues as Novel Androgen
Receptor Antagonists with Potential as Anti-Prostate Cancer Agents.”
Journal of Medicinal
Chemistry
, vol. 45, no. 23, 2002, pp. 5037–5042., doi:10.1021/jm020200g.
23) Zhou, Jinming, et al. “Design and Synthesis of Androgen Receptor Antagonists with Bulky
Side Chains for Overcoming Antiandrogen Resistance.”
Journal of Medicinal Chemistry
, vol. 52,
no. 17, Oct. 2009, pp. 5546–5550., doi:10.1021/jm801218k.
24)
Baell, Jonathan, and Michael A. Walters.
Chemistry: Chemical Con Artists Foil Drug
Discovery ...
www.nature.com/articles/513481a.
25)
Baell, Jonathan B., and Georgina A. Holloway.
New Substructure Filters for Removal of Pan
Assay ...
pubs.acs.org/doi/abs/10.1021/jm901137j.
26)
Bottegoni, Giovanni, et al. “Four-Dimensional Docking: a Fast and Accurate Account of
Discrete Receptor Flexibility in Ligand Docking.”
Journal of Medicinal Chemistry
, U.S. National
Library of Medicine, 22 Jan. 2009,
www.ncbi.nlm.nih.gov/pmc/articles/PMC2662720/
.
27) Elshan, N. G. R. Dayan, et al. “Molecules Targeting the Androgen Receptor (AR) Signaling
Axis beyond the AR
-
Ligand Binding Domain.”
Medicinal Research Reviews
, vol. 39, no. 3, 2018,
pp. 910–960., doi:10.1002/med.21548.
28) Logothetis, Christopher, et al. “Current Perspectives on Bone Metastases in Castrate-Resistant
Prostate Cancer.”
Cancer and Metastasis Reviews
, vol. 37, no. 1, 2018, pp. 189–196.,
doi:10.1007/s10555-017-9719-4.
47
29) Jayadevappa, Ravishankar, et al. “Comparative Effectiveness of Prostate Cancer Treatments
for
Patient-Centered
Outcomes.”
Medicine
,
vol.
96,
no.
18,
2017,
doi:10.1097/md.0000000000006790
30) Ito, Yusuke, and Marianne D Sadar. “Enzalutamide and Blocking Androgen Receptor in
Advanced Prostate Cancer: Lessons Learnt from the History of Drug Development of
Antiandrogens.”
Research and Reports in Urology
, Volume 10, 2018, pp. 23–32.,
doi:10.2147/rru.s157116.
31) Shi, Q., et al. “Novel Anti-Prostate Cancer Curcumin Analogues That Enhance Androgen
Receptor Degradation Activity.”
Anti-Cancer Agents in Medicinal Chemistry
, vol. 9, no. 8, Jan.
2009, pp. 904–912., doi:10.2174/187152009789124655.
32) Neves, Marco A C, et al. “Docking and Scoring with ICM: the Benchmarking Results and
Strategies for Improvement.”
Journal of Computer-Aided Molecular Design
, U.S. National
Library of Medicine, June 2012.
33) Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and
Olson, A. J. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor
flexiblity.
J. Computational Chemistry
2009,
16
: 2785-91
34) Li, Huifang, et al. “Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-
Binding Domain of the Human Androgen Receptor.”
Journal of Medicinal Chemistry
, vol. 57, no.
15, Apr. 2014, pp. 6458–6467., doi:10.1021/jm500802j.
35)
Morris, Garrett M. “AutoLigand: A Ligand Site Finder and Drug Development
Tool.”
AutoDock
, autodock.scripps.edu/resources/autoligand.
48
36) Pierce, Brian G, et al. “ZDOCK Server: Interactive Docking Prediction of Protein-Protein
Complexes and Symmetric Multimers.”
Bioinformatics (Oxford, England)
, Oxford University
Press, 15 June 2014, https://www.ncbi.nlm.nih.gov/pubmed/24532726.
37) Ruiz-Carmona, Sergio, et al. “RDock: A Fast, Versatile and Open Source Program for Docking
Ligands to Proteins and Nucleic Acids.”
PLOS Computational Biology
, Public Library of Science,
http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1003571.
38) Protein Docking Using Case-Based Reasoning.
A.W. Ghoorah, M. Smail-Tabbone, M.-D.
Devignes,
D.W.
Ritchie,
(2013).
Proteins:
Structure,
Function,
Bioinformatics,
DOI: 10.1002/prot.24433.
39) G.C.P van Zundert, J.P.G.L.M. Rodrigues, M. Trellet, C. Schmitz, P.L. Kastritis, E. Karaca,
A.S.J. Melquiond, M. van Dijk, S.J. de Vries and A.M.J.J. Bonvin (2016). "The HADDOCK2.2
webserver: User-friendly integrative modeling of biomolecular complexes." J. Mol. Biol.,
428
,
720-725 (2015).
40) Mcmartin, Colin, and Regine S. Bohacek. “QXP: Powerful, Rapid Computer Algorithms for
Structure-Based Drug Design.”
Journal of Computer-Aided Molecular Design
, vol. 11, no. 4,
1997, pp. 333–344., doi:10.1023/a:1007907728892.
41) Ring CS, Sun E, McKerrow JH, et al. Structure-based inhibitor design by using protein models
for the development of antiparasitic agents. Proc Natl Acad Sci U S A. 1993;90:3583–3587. doi:
10.1073/pnas.90.8.3583.
42) Cinar, Bekir, et al. “Identification of a Negative Regulatory Cis-Element in the Enhancer
Region of the Prostate-Specific Antigen Promoter: Implications for Intersection of Androgen
49
Receptor and Nuclear Factor-KappaB Signalling in Prostate Cancer Cells.”
Biochemical Journal
,
vol. 379, no. 2, 2004, pp. 421–431., doi:10.1042/bj200316
|